Product Description
AVE8112 is a PDE4 inhibitor that was in development by the pharmaceutical company Sanofi for the treatment of cognitive impairment in AlzheimerÕs disease patients and had shown promise in several pre-clinical models. The Michael J. Fox Foundation partnered with Sanofi to develop AVE8112 for the treatment of cognitive impairment in ParkinsonÕs patients.Ê (Sourced from: https://www.michaeljfox.org/grant/phase-i-b-clinical-trial-ave8112-cognitive-impairment-parkinsons-disease)
Mechanisms of Action: PDE4 Inhibitor
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Michael J. Fox Foundation for Parkinson's Research
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Parkinson's Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01803945 |
MJFF AVE8112 MAD PD | P1 |
Terminated |
Parkinson's Disease |
2015-06-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|